Form 13-F position report

BIOAGE LABS INC

Reported by CANTOR FITZGERALD L P

BIOA CUSIP 09077V100 Manager CIK 0001024896

Reported 0 shares, down 200,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2025-06-30 826000
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

2 quarters
Quarterly reported position history for BIOAGE LABS INC held by CANTOR FITZGERALD L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -200,000 (-100.0%) 0 $0 2025-11-14
Q2 2025 New 200,000 +200,000 (0.0%) 0.01% $826,000 2025-08-14

Who else reported the position

97 managers reported BIOAGE LABS INC for Q3 2025.

Managers reporting BIOAGE LABS INC in Q3 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AH Capital Management L L C Unchanged 3,233,170 0 1.36% $19,011,040 5 qtrs
Sofinnova Investments Inc Reduced 2,293,788 -11,113 0.74% $13,487,473 5 qtrs
Cormorant Asset Management LP Unchanged 2,140,605 0 0.87% $12,586,757 5 qtrs
ADAR1 Capital Management LLC Reduced 1,880,073 -57,050 1.04% $11,054,829 4 qtrs
VANGUARD GROUP INC Added 1,651,247 +93,694 < 0.01% $9,709,331 5 qtrs
TANG CAPITAL MANAGEMENT LLC Unchanged 1,600,000 0 0.36% $9,408,000 4 qtrs
BlackRock Inc Reduced 1,279,621 -7,796 < 0.01% $7,524,172 4 qtrs
ORBIMED ADVISORS LLC Reduced 790,901 -131,058 0.11% $4,650,498 5 qtrs
Sands Capital Ventures LLC Unchanged 786,353 0 1.01% $4,623,756 5 qtrs
Pivotal bioVenture Partners Investment Advisor LLC Unchanged 653,374 0 2.22% $3,841,839 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.